Clinical trials: Pharmacological Action, active
Solid Tumor, Non-Small Cell Lung Cancer
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in…
- Conditions
- Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma
- Trial name
- NCT04198766
- Testing
- INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg
- Where
- 60 sites in United States, Singapore and 2 more
- Volunteers
- 340 people
- Sponsor
- Inhibrx Biosciences, Inc
Advanced Solid Tumor, Diffuse Large B Cell Lymphoma
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy…
- Conditions
- Advanced Solid Tumor, Diffuse Large B Cell Lymphoma, Lymphoma, T-Cell, Mesothelioma, Malignant
- Trial name
- NCT04104776
- Testing
- Tulmimetostat, Enzalutamide
- Where
- 80 sites in United States, France and 5 more
- Volunteers
- 300 people
- Sponsor
- Novartis Pharmaceuticals
Coronary Disease, Heart Diseases
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Myocardial Ischemia
- Trial name
- PIV-EPIC (NCT06535568)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- Italy
- Volunteers
- 576 people
- Sponsor
- Fondazione Ricerca e Innovazione Cardiovascolare ETS
Spinal Cord Injury, Spinal Cord Injuries
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
This pilot study will determine the feasibility of implementing a combinatory rehabilitation strategy involving testosterone replacement therapy (TRT) with locomotor training (LT; walking on a treadmill with assistance and…
- Conditions
- Spinal Cord Injury, Spinal Cord Injuries, Trauma, Nervous System, Wounds and Injury
- Trial name
- NCT04460872
- Testing
- Testosterone Enanthate, Locomotor Training
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- North Florida Foundation for Research and Education
Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
This Phase 2, open-label, randomized study in non-small-cell lung cancer (NSCLC) is designed to evaluate the efficacy and safety of an intravenously delivered oncolytic vaccinia virus, Olvi-Vec, followed by platinum-doublet…
- Conditions
- Advanced Non-squamous Non-small-cell Lung Cancer, Advanced Squamous Non-Small Cell Lung Carcinoma, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Squamous Non-Small Cell Lung Carcinoma
- Trial name
- VIRO-25 (NCT06463665)
- Testing
- Olvimulogene nanivacirepvec, Platinum chemotherapy: carboplatin or cisplatin, Non-platinum chemotherapy: paclitaxel or nab-paclitaxel for squamous cell NSCLC or pemetrexed for nonsquamous cell NSCLC
- Where
- 15 sites in United States
- Volunteers
- 142 people
- Sponsor
- Genelux Corporation
Suicide, Depressive Disorder, Treatment-Resistant
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
Background: Major depressive disorder (MDD) is a serious mental illness that can put people at risk of self-harm and death. Many drugs are used to treat MDD, but it can take a long time for them to be effective.
- Conditions
- Suicide, Depressive Disorder, Treatment-Resistant, Ketamine, Molecular Mechanisms of Pharmacological Action
- Trial name
- NCT06511908
- Testing
- (2R,6R)-hydroxynorketamine (0.25 to 2.0 mg/kg)
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Mental Health (NIMH)
Breast Cancer; HER2-positive; Metastatic
Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer (DESTINY-Breast09)
The study will evaluate the efficacy and safety of trastuzumab deruxtecan (also known as T-DXd, DS-8201a), either alone or in combination with pertuzumab, in treating patients with Human epidermal growth factor receptor 2…
- Trial name
- NCT04784715
- Testing
- Trastuzumab deruxtecan, Taxane, Pertuzumab
- Where
- 283 sites in United States, Argentina and 25 more
- Volunteers
- 1,157 people
- Sponsor
- AstraZeneca
Pharmacologic Action
Efficacy and Safety of Ultrasound-Guided Pharmacopuncture as an Adjunctive Therapy in Inpatients With Post-Traffic Accident Tension-Type Headache
The purpose of this study is to reveal the effectiveness and safety of ultrasound-guided pharmacopuncture for patients with tension-type headache caused by a traffic accident.
- Trial name
- NCT07893496
- Testing
- Cervicocranial ultrasound-guided pharmacopuncture, Oriental medicine integrated treatment
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Jaseng Medical Foundation
Breast Neoplasms, Breast Cancer
Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer
This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.
- Conditions
- Breast Neoplasms, Breast Cancer, HER2-positive Early Breast Cancer
- Trial name
- NCT05113251
- Testing
- Trastuzumab Deruxtecan, Paclitaxel, Trastuzumab
- Where
- 145 sites in United States, Brazil and 16 more
- Volunteers
- 927 people
- Sponsor
- AstraZeneca
Behavioral Symptoms, Suicide
Natural History of Depression, Bipolar Disorder and Suicide Risk
Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments.
- Conditions
- Behavioral Symptoms, Suicide, Self-Injurious Behavior, Sensory System Agents
- Trial name
- NCT06462196
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Mental Health (NIMH)
KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study treatments (TNO155 and tislelizumab) in advanced…
- Conditions
- KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal, Cancer of Lung
- Trial name
- KontRASt-01 (NCT04699188)
- Testing
- JDQ443, TNO155, tislelizumab
- Where
- 38 sites in United States, Australia and 14 more
- Volunteers
- 344 people
- Sponsor
- Novartis Pharmaceuticals
Nausea and Vomiting, Nausea
Broadening Antiemetics Research by Comparing the Effectiveness of Fosaprepitant and Metoclopramide
The study team proposes a double-blind, comparative effectiveness, randomized controlled trial (RCT) to address the following goal: to determine the relative efficacy and adverse event profile of fosaprepitant compared to the…
- Conditions
- Nausea and Vomiting, Nausea, Vomiting
- Trial name
- BARF RCT (NCT06740812)
- Testing
- Fosaprepitant for Injection, Metoclopramide Injection
- Where
- United States
- Volunteers
- 212 people
- Sponsor
- Montefiore Medical Center
Heart Failure, Heart Failure, Diastolic
A Preliminary Study for INFORMED
Investigators will determine whether N-of-1 trials, as a pragmatic, participant-centered approach to medication optimization that can overcome key barriers of deprescribing, can lead to increased participant confidence regarding…
- Conditions
- Heart Failure, Heart Failure, Diastolic, Heart Failure With Preserved Ejection Fraction, Cardiac Failure
- Trial name
- PRE-INFORMED (NCT05585125)
- Testing
- Beta blocker
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Weill Medical College of Cornell University
Neuromuscular Agents, Peripheral Nervous System Agents
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence.
- Conditions
- Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
- Trial name
- PLATINUM EU (NCT07210463)
- Testing
- NT 201
- Where
- 26 sites in France, Germany and 2 more
- Volunteers
- 300 people
- Sponsor
- Merz Aesthetics GmbH
Basic Science
LSD Occupancy of the Serotonin 2A Receptor in the Human Brain
The investigators wish to quantify the relation between administered dose of lysergic acid diethylamide (LSD), plasma LSD levels, and occupancy at the serotonin 2A receptor (5-HT2AR) using [11C]CIMBI-36 positron emission…
- Trial name
- dOccLS (NCT05953038)
- Testing
- Lysergic Acid Diethylamide Tartrate
- Where
- Denmark
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Delirium, Cognitive Dysfunction
Cognitive Outcomes After Dexmedetomidine Sedation in Cardiac Surgery Patients
Anesthesia is a drug induced, reversible, comatose state that facilitates surgery and it is widely assumed that cognition returns to baseline after anesthetics have been eliminated.
- Conditions
- Delirium, Cognitive Dysfunction, Cognition Disorder, Neurocognitive Disorders
- Trial name
- CODEX (NCT04289142)
- Testing
- Dexmedetomidine Hydrochloride Group
- Where
- 8 sites in Canada
- Volunteers
- 2,400 people
- Sponsor
- Sunnybrook Health Sciences Centre
Giant Cell Arteritis
Abatacept for the Treatment of Giant Cell Arteritis
This randomized, double-blind, placebo-controlled trial will seek to determine the efficacy of abatacept in GCA. To examine this objective, 62 eligible patients who have newly diagnosed or relapsing GCA within 8 weeks prior to…
- Trial name
- NCT04474847
- Testing
- Abatacept
- Where
- 10 sites in United States, Canada and 1 more
- Volunteers
- 78 people
- Sponsor
- University of Pennsylvania
Spinal Cord Injury, Spinal Cord Injuries
Testosterone Therapy With or Without Finasteride After Spinal Cord Injury: TRT-SCI Trial
Spinal cord injury (SCI) results in lower limb muscle loss, bone loss, and high fat mass that impede the recovery of physical function, increase bone fracture risk, and worsen health and quality of life.
- Conditions
- Spinal Cord Injury, Spinal Cord Injuries, Injuries, Spinal Cord, Spinal Cord Contusion
- Trial name
- TRT-SCI (NCT07742553)
- Testing
- testosterone cypionate, finasteride
- Where
- 4 sites in United States
- Volunteers
- 300 people
- Sponsor
- VA Office of Research and Development
Pharmacologic Action
The Effectiveness and Safety of Pharmacopuncture on Inpatients With Acute Knee Pain Caused by Traffic Accidents
The purpose of this study is to reveal the effectiveness and safety of knee herbal acupuncture for patients with acute knee joint pain caused by a traffic accident.
- Trial name
- NCT06931951
- Testing
- Knee Pharmacoacupuncture, Oriental medicine integrated treatment
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Jaseng Medical Foundation
Neuromuscular Agents, Peripheral Nervous System Agents
A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States
The purpose of this study is to assess the safety and efficacy of NT 201 compared with placebo in participants with moderate to severe platysma prominence.
- Conditions
- Neuromuscular Agents, Peripheral Nervous System Agents, Physiological Effects of Drugs, Acetylcholine Release Inhibitors
- Trial name
- PLATINUM US (NCT07122193)
- Testing
- NT 201
- Where
- 28 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Merz North America, Inc.